Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study to Evaluate the Efficacy and Safety od BZ371B in Patients With Acute Respiratory Distress System (ARDS) in Mechanical Ventilation, Due to Respiratory Infections

X
Trial Profile

Clinical Study to Evaluate the Efficacy and Safety od BZ371B in Patients With Acute Respiratory Distress System (ARDS) in Mechanical Ventilation, Due to Respiratory Infections

Status: Discontinued
Phase of Trial: Phase 0

Latest Information Update: 05 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BZ 371B (Primary)
  • Indications Adult respiratory distress syndrome; COVID-19 pneumonia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biozeus
  • Most Recent Events

    • 05 Jun 2023 Status changed from recruiting to discontinued.
    • 05 Aug 2022 Planned End Date changed from 1 Jun 2023 to 1 Nov 2023.
    • 05 Aug 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top